ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Colonic Cancer
Cancer
Lung Cancer
Neoplasm Metastasis
Non-Small-Cell Lung Carcinoma
Adenocarcinoma

Colon Cancer trials near Baltimore, MD, USA:

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2)

(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...

Enrolling
Colonic Neoplasms
Neoplasms, Colon
Drug: CAPEOX
Biological: Dostarlimab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Bethesda, Maryland, United States and 250 other locations

A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions....

Active, not recruiting
Colon Cancer
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer
Drug: Nivolumab
Drug: Copanlisib

Phase 1, Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

(PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer...

Enrolling
Colon Cancer
Metastatic Colon Cancer
Drug: BBO-8520
Drug: Pembrolizumab

Phase 1

TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Fairfax, Virginia, United States and 14 other locations

or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcino...

Enrolling
Pancreatic Cancer
Colorectal Cancer
Drug: KRAS Vaccine with Poly-ICLC adjuvant
Drug: Botensilimab

Phase 1

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, an...

Active, not recruiting
Any Solid Tumor
Glioma
Drug: LY3410738
Drug: Gemcitabine

Phase 1

Lilly
Lilly

Baltimore, Maryland, United States and 32 other locations

is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: RMC-6236
Drug: RMC-9805

Phase 1

Revolution Medicines
Revolution Medicines

Baltimore, Maryland, United States and 16 other locations

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...

Active, not recruiting
Any Solid Tumor
Colon Cancer
Drug: LOXO-292

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Baltimore, Maryland, United States and 83 other locations

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: RMC-6236

Phase 1

Revolution Medicines
Revolution Medicines

Baltimore, Maryland, United States and 15 other locations

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of ....

Enrolling
Advanced Cancer
Endometrial Cancer
Drug: PHN-010

Phase 1

Pheon Therapeutics

Fairfax, Virginia, United States and 4 other locations

This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors....

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer
Drug: Assigned interventions

Phase 1

Revolution Medicines
Revolution Medicines

Fairfax, Virginia, United States and 27 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems